R&D | April 22, 2026
Pfizer unleashes wave of breakthrough cancer data at ASCO 2026
Pharma giant targets new standards of care
Pharma giant targets new standards of care
The long-term exposure to fine particulate matter (PM2.5) increases overall cancer risk by 11%
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
The license is valid for five years, effective from April 9, 2026
The Stealth AXiS surgical navigation system was recently cleared by the US Food and Drug Administration (FDA) for cranial procedures in the United States
The presentations underscore the company’s deep expertise in dermatology and immunology
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
The new LEED Gold-certified building will serve as CordenPharma Colorado’s sole tenant
The new lineup features everything from the Color Fixation and Hair Therapy ranges to the Balanced Cleansing Shampoo and Nourishment & Protection Conditioner
Subscribe To Our Newsletter & Stay Updated
